- Home
- BST vs ABCL Comparison
BST vs ABCL Comparison
Compare BST & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BST
- ABCL
- Stock Information
- Founded
- BST 2014
- ABCL 2012
- Country
- BST United States
- ABCL Canada
- Employees
- BST N/A
- ABCL N/A
- Industry
- BST Finance Companies
- ABCL Biotechnology: Pharmaceutical Preparations
- Sector
- BST Finance
- ABCL Health Care
- Exchange
- BST Nasdaq
- ABCL Nasdaq
- Market Cap
- BST 1.3B
- ABCL 1.1B
- IPO Year
- BST N/A
- ABCL 2020
- Fundamental
- Price
- BST $38.84
- ABCL $4.69
- Analyst Decision
- BST
- ABCL Strong Buy
- Analyst Count
- BST 0
- ABCL 5
- Target Price
- BST N/A
- ABCL $8.75
- AVG Volume (30 Days)
- BST 88.5K
- ABCL 6.8M
- Earning Date
- BST 01-01-0001
- ABCL 08-07-2025
- Dividend Yield
- BST 7.72%
- ABCL N/A
- EPS Growth
- BST N/A
- ABCL N/A
- EPS
- BST N/A
- ABCL N/A
- Revenue
- BST N/A
- ABCL $23,114,000.00
- Revenue This Year
- BST N/A
- ABCL N/A
- Revenue Next Year
- BST N/A
- ABCL $71.11
- P/E Ratio
- BST N/A
- ABCL N/A
- Revenue Growth
- BST N/A
- ABCL N/A
- 52 Week Low
- BST $27.87
- ABCL $1.89
- 52 Week High
- BST $39.59
- ABCL $5.82
- Technical
- Relative Strength Index (RSI)
- BST 63.62
- ABCL 60.12
- Support Level
- BST $38.25
- ABCL $4.67
- Resistance Level
- BST $39.13
- ABCL $5.19
- Average True Range (ATR)
- BST 0.33
- ABCL 0.41
- MACD
- BST -0.02
- ABCL 0.01
- Stochastic Oscillator
- BST 73.66
- ABCL 42.05
About BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.